Privo Technologies Completes Phase 2 Run-In in PRV111 Oral Cancer Trial, Highlighting Potential to Spare Patients from Surgery
Privo Technologies, Inc. a leader in localized cancer therapies, today announced the completion of enrollment in Arm 1 of the Phase 2 run-in portion of its ongoing Phase 2/3 clinical trial (CLN-004) evaluating PRV111, a nano-engineered chemotherapy patch designed to...